These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22120678)

  • 61. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 17 AAG for HSP90 inhibition in cancer--from bench to bedside.
    Usmani SZ; Bona R; Li Z
    Curr Mol Med; 2009 Jun; 9(5):654-64. PubMed ID: 19601813
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S; Workman P
    Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
    Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
    Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolving novel anti-HER2 strategies.
    Jones KL; Buzdar AU
    Lancet Oncol; 2009 Dec; 10(12):1179-87. PubMed ID: 19959074
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hsp90 inhibitors in breast cancer: a systematic review.
    Zagouri F; Sergentanis TN; Chrysikos D; Papadimitriou CA; Dimopoulos MA; Psaltopoulou T
    Breast; 2013 Oct; 22(5):569-78. PubMed ID: 23870456
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
    Xiao L; Lu X; Ruden DM
    Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
    Gartner EM; Silverman P; Simon M; Flaherty L; Abrams J; Ivy P; Lorusso PM
    Breast Cancer Res Treat; 2012 Feb; 131(3):933-7. PubMed ID: 22083229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
    Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
    Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
    Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
    Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
    Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
    Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
    Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.